van der Zijden, Charlène J. http://orcid.org/0000-0002-3650-8303
Lagarde, Sjoerd M.
Hermus, Merel
Kranenburg, Leonieke W.
van Lanschot, J. Jan B.
Mostert, Bianca
Nuyttens, Joost J. M. E.
Oudijk, Lindsey
van der Sluis, Pieter C.
Spaander, Manon C. W.
Valkema, Maria J.
Valkema, Roelf
Wijnhoven, Bas P. L.
,
Dekker, Jan Willem T.
Fiets, Willem E.
Hartgrink, Hendrik H.
Hazen, Wouter L.
Kouwenhoven, Ewout A.
Nieuwenhuijzen, Grard A. P.
Rosman, Camiel
van Sandick, Johanna W.
Sosef, Meindert N.
van der Zaag, Edwin S.
Funding for this research was provided by:
Erasmus MC foundation (Erasmus MC foundation)
Stichting Theia (2021296)
Achmea (Z798)
Article History
Received: 22 June 2022
Accepted: 15 March 2023
First Online: 10 April 2023
Declarations
:
: The study will be performed in accordance with the Declaration of Helsinki (64<sup>th</sup> World Medical Association General Assembly, Fortaleza, Brazil, October 2013). Approval has been obtained by the ethical committee (Institutional Review Board) at the Erasmus MC Cancer Institute on March 8, 2021 (MEC-2021–0068). Written informed consent will be obtained from all patients.
: Not applicable.
: BW received a research grant from Bristol-Myers Squibb and consulting fees.BM received research grants from Bristol-Myers Squibb, Sanofi and Pfizer and consulting fees from Lilly and Servier.MS received a research grant from Medtronic.JvL and MJV received research grants from KWF Dutch Cancer Society and The Netherlands Organization for Health Research and Development (ZonMw).CR received research grants from The Netherlands Organization for Health Research and Development (ZonMw), Johnson & Johnson and Medtronic.SL is editorial board member of BMC Cancer.All other authors declared to have no competing interests.